Korean Biotech on Korea Invest Insights

Korean Biotech Sector Investment Thesis — Not a 'Buy Good Tech' Market. A 'Buy What the Market Has Underpriced' Market (2026-05-12)

Tue, 12 May 2026 13:30:00 +0900

🔗 Related reading: Pamicell Part 3 — 1Q26 Earnings Confirmation · Rejuran — PharmaResearch PN Skin Booster · Easy Bio Part 1 · Easy Bio Part 2 · ROE-25% Screen — 4 Names That Pass 9 Filters

Korean biotech is not a broad-beta buy regime right now. It’s a selection regime where only data-, BD-, royalty-, or CDMO-validated names work. End-of-May stacks ASCO (May 29-Jun 2), EASL (May 27-30), and EHA abstract releases (May 12 / Jun 2) into one window. The core principle is simple — you’re not buying clinical success probability. You’re buying the gap between market-implied success probability and your internal estimate.

TL;DR

The sector is in selection regime, not broad-buy regime. Conference catalysts, global regulatory change, and Korea-specific positioning reflexivity all interact in the same window.
End-of-May conference data is the first price-setting window. ASCO general abstracts release May 21 17:00 ET (May 22 06:00 KST); congress May 29-Jun 2. EASL May 27-30. EHA general abstracts May 12 22:30 KST, late-breakers June 2 22:30 KST.
Five concurrent theses. (1) Oncology BD — LegoChem Bio, Voronoi, GI Innovation, Lunit; (2) MASH 48-week histology — D&D Pharmatech DD01; (3) SC-conversion royalty — Alteogen; (4) CDMO + biosimilars — Samsung Biologics, Celltrion; (5) FDA regulatory-innovation long option.
The market’s biggest mispricing is “abstract acceptance ≠ data quality.” ORR, PFS, OS, DoR, Grade 3/4 AEs, discontinuation rates, and biomarker-defined subgroups determine post-release price action.
The avoid list is clear. Names already running on abstract acceptance alone, names with only preclinical / platform narrative and no human data, names with short cash runway and large CB/BW overhang, names recycling “global big-pharma interest” without partners or upfronts, names entering hot biotech ETF flows.
Core discipline. Don’t believe the tech; believe the data and the cash runway.

1. Three forces operating simultaneously in Korean biotech right now

1.1 Conference data re-pricing

ASCO 2026 runs May 29-Jun 2. General abstracts release May 21 17:00 ET — May 22 06:00 KST. EASL Congress 2026 runs May 27-30 in Barcelona and online.

End-of-May is the window where oncology (ASCO) and liver-fibrosis / MASH (EASL) data hit the same week. The 1-2 weeks between abstract release and main-stage presentation is the first price-setting window for Korean biotech event names.

1.2 Global regulatory environment shift

FDA in March 2026 released a draft guidance on simplifying biosimilar development by reducing unnecessary pharmacokinetic (PK) testing. FDA stated this can cut developer PK-trial costs by up to 50%, or roughly $20M.

In April 2026, FDA announced the Real-Time Clinical Trials initiative — a proof-of-concept and pilot program for real-time submission of trial-data signals to FDA. The broader direction favors biosimilar and clinical-development efficiency.

1.3 Korean market positioning reflexivity

KRX Data Marketplace publishes short-sale, flow, and investor-segment data, and Korean short-selling has been re-enabled since March 31, 2025. Korean biotech event names see short-sale, securities-lending, ETF flow, and retail-overheating amplifying volatility. Data analysis and flow analysis cannot be separated for the asset class to make sense.

2. The five concurrent theses

2.1 In one line

Thesis	Mechanism	Representative names
Data → BD	Trial data re-prices big-pharma licensing optionality	LegoChem Bio, Voronoi, GI Innovation
Disease-specific binary	One readout shifts the entire equity value	D&D Pharmatech, Yuhan MASH read-through
Royalty infrastructure	Repeatable royalty structure, not single-trial success	Alteogen
Cash-flow bio	Real revenue / orders / utilization protect valuation	Samsung Biologics, Celltrion, Samsung Bioepis line
FDA regulatory-innovation option	Long-dated optionality on clinical-development time-value	Names with US clinical infrastructure

2.2 The avoid list

Avoid	Why
Names already running on abstract acceptance alone	Presentation format ≠ data quality
Preclinical / platform narrative names with no human data	BD optionality is low without human data
Short cash runway + large CB/BW overhang	Dilution destroys shareholder value before any good readout
Names recycling “global big-pharma interest” with no contracts	Without counterparty, upfront, or royalty terms, the claim is empty
Names entering hot biotech ETF flows	Look like alpha on the way up; forced sellers on the way down

3. The framework for looking at Korean biotech

[Capital flows]
Big-pharma patent cliff / FDA deregulation / Conference events / ETF + retail flow / Short-sale re-enabled
 ↓
[Value chain]
Basic tech → candidates → preclinical → Phase 1/2/3 → approval → manufacturing → sales / royalty
 ↓
[Choke points]
Human PoC / trial design / safety / manufacturing CMC / IP / cash runway / partnering
 ↓
[P×Q×C]
P = drug price / licensing $ / royalty rate
Q = patients / indication expansion / prescribing conversion / backlog
C = trial cost / cost of goods / dilution cost / time cost

The discipline: separate technology → trials → regulation → commercialization → public-market price. Good science doesn’t equal a good stock. The recurring failure mode in Korean biotech isn’t a failure to understand the science — it’s a failure to price data maturity and funding risk.

4. Thesis 1 — Oncology BD axis

4.1 Core logic

Oncology is where global big-pharma BD demand most directly applies. ADCs, bispecifics, immuno-oncology combinations, EGFR/CNS-penetrant targeted therapies, and AI biomarkers can all re-price licensing expectations through ASCO data.

4.2 Names

Name	Ticker	Catalyst	Read
LegoChem Biosciences	141080	ASCO ADC data + partner read-through	Korea’s flagship ADC platform; data quality + partner optionality drives value
Voronoi	310210	VRN11 brain-mets / CNS data	EGFR-mutant NSCLC + CNS-penetrance verification event
GI Innovation	358570	GI-101A ASCO Rapid Oral Abstract	Phase 1 — format weight matters less than efficacy / safety read
Lunit	328130	ASCO AI-biomarker studies	Companion-diagnostics / AI-biomarker validation rather than NCE licensing

Voronoi disclosed in pipeline materials that VRN11 brain-metastasis clinical data is scheduled at ASCO 2026 May, and noted a DCR of 100% in 11 brain-mets / leptomeningeal-mets patients in the ≥160mg cohort. The number is interesting but the patient count is small; final judgment requires the full ASCO dataset and follow-up duration.

GI Innovation disclosed that GI-101A Phase 1 data was accepted as an ASCO 2026 Rapid Oral Abstract. Phase 1 = safety / dose / early efficacy signal stage — the oral-presentation format itself shouldn’t trigger a valuation re-rating.

Lunit is reportedly presenting 5 abstracts based on the Lunit SCOPE platform at ASCO 2026, with one biliary-tract cancer study selected as a Rapid Oral Presentation. This is AI-biomarker clinical-utility validation, not NCE licensing.

4.3 Market mispricing variable

The market overweights “abstract acceptance” and underweights data quality. What actually matters: ORR, PFS, OS, DoR, Grade 3/4 AEs, discontinuation rates, dose-response, biomarker-defined subgroups.

4.4 Red-team

ADCs — linker / payload / toxicity profile can dominate the target choice.
Phase 1 single-arm data leans heavily on historical controls.
Small patient counts + short follow-up can produce post-print rallies without real BD substance.
Competitor compounds advancing faster into Phase 2/3 can leave Korean assets in the second tier even with good data.

5. Thesis 2 — MASH / obesity axis

5.1 Core logic

MASH (metabolic dysfunction-associated steatohepatitis) is the follow-on alpha after obesity / GLP-1. In MASH, the value driver is not weight loss or liver fat — it’s biopsy-based fibrosis improvement and MASH resolution.

EASL Congress 2026 runs May 27-30. For Korean investors, the highest-impact event is D&D Pharmatech DD01.

5.2 Names

Name	Ticker	Catalyst	Read
D&D Pharmatech	347850	DD01 Phase 2 48-week EASL Late-Breaking Abstract	Largest May binary in Korean biotech
Yuhan	000100	MASH candidate read-through	Re-development possibility of returned asset
Hanmi Pharm	128940	efinopegdutide presentation delay possibility	May conference momentum weakened
Olix Pharmaceuticals	226950	RNAi-based obesity / MASH option	Read-through play more than direct data

D&D Pharmatech disclosed that the DD01 Phase 2 48-week patient dataset is database-locked and will be presented as a Late-Breaking Abstract at EASL Congress 2026. The company indicated key data including biopsy-confirmed liver-fibrosis improvement will be disclosed to accelerate global partnering.

5.3 Market mispricing variable

The market over-reacts to “GLP-1” as a category. The actual investment point for DD01 is not the GLP-1 theme — it’s whether MASH histological improvement materializes.

5.4 Red-team

If 48-week data shows good liver-fat / weight but weak fibrosis improvement, valuation re-rating is constrained.
MASH endpoints are demanding; even a strong Phase 2 still faces large Phase 3 cost and duration.
If pre-print sentiment over-runs, even a good readout can produce sell-the-news.

6. Thesis 3 — Alteogen and SC-conversion royalty infrastructure

6.1 Core logic

The Alteogen-style SC (subcutaneous) conversion platform differs from conventional clinical biotech. Value is not from one drug’s clinical-success probability — it’s from capturing as royalty the economic value of administration convenience, clinic throughput, and patient chair-time savings when IV formulations convert to SC.

6.2 Market mispricing

The market tends to read Alteogen as a single-drug (Keytruda SC) theme. The variable that actually matters is whether the SC-conversion platform is repeatable. As prescription-conversion data accumulates, Alteogen re-rates from “single-event bio” to “royalty DCF.”

6.3 Red-team

Low real-world prescription-conversion damages royalty expectations.
Competitor SC platforms or in-house formulation extensions erode platform moat.
High market recognition already; “good company” and “good entry price” are separate questions.

7. Thesis 4 — CDMO + biosimilars cash-flow axis

7.1 Core logic

CDMO (contract development and manufacturing) and biosimilars are more defensive than event biotech. But they aren’t just defensive — they’re a structural growth axis combining global biopharma supply chain, FDA deregulation, and manufacturing quality trust.

Samsung Biologics’ 1Q26 CDMO revenue was ₩1,257.1bn with OP ₩580.8bn — full utilization on plants 1-4 plus project execution drove the print.

FDA’s March 2026 biosimilar-simplification draft guidance directionally lowers biosimilar development cost and duration. Long-term constructive for Celltrion, Samsung Bioepis, and the rest of the biosimilar field.

7.2 Market mispricing

The market often reads CDMO as a “defensive biotech” trade. The actual industry is quality + delivery + capacity + regulatory trust — customers buy “won’t fail manufacturing,” not “cheapest price.”

7.3 Red-team

Samsung Biologics is high-quality, but labor / quality / production disruption risks discount new-order trust.
Biosimilar deregulation lifts the field but can accelerate ASP compression.
FDA deregulation isn’t an automatic Korean-corporate win — execution matters.

8. Thesis 5 — FDA regulatory innovation as long-dated option

The FDA Real-Time Clinical Trials initiative aims to enable real-time trial-data submission and reduce administrative delay. FDA released the PoC and pilot on April 28, 2026.

If clinical-development dead-time falls, rNPV time-value discount can soften. But this is still early-stage regulation. Actual beneficiaries are most likely names with US clinical infrastructure, data-management capability, and regulatory bandwidth.

Red-team: pilot scope may be narrow; Korean small-to-mid-cap biotech likely won’t be early adopters in the FDA real-time pipeline; the regime change lowers time cost but doesn’t raise approval probability itself.

9. May-June conference calendar

Date (KST)	Event	Field	Impact	Names
2026-05-11 ~ 05-15	ASGCT 2026	Cell + gene + RNA	3/5	Argonomix, CGT / RNA platforms
2026-05-12 22:30	EHA general abstracts	Hematology	3/5	Hematology, CAR-T, ADC
2026-05-22 06:00	ASCO general abstracts	Oncology	5/5	LegoChem Bio, Voronoi, GI Innovation, Lunit
2026-05-27 ~ 05-30	EASL 2026	MASH / liver	5/5	D&D Pharmatech, Yuhan, Hanmi read-through
2026-05-29 ~ 06-02	ASCO 2026	Oncology	5/5	Oncology platforms broadly
2026-06-02 22:30	EHA late-breaking	Hematology	3/5	Hematology / cell therapy
2026-06-05 onward	ADA 2026	Diabetes / obesity	3/5	Hanmi, Ildong, Olix, D&D read-through

ASGCT 2026 — Boston, major cell + gene therapy congress. EHA 2026 main congress runs Jun 11-14 but the investment events (abstract releases) fall within the next month.

9.1 Event-trading principles

Window	Principle
3-4 weeks pre-event	Build event list; check if price has already moved
Pre-abstract	Don’t chase pre-running names; engage only under-positioned ones
Immediately post-abstract	Verify endpoints, patient counts, safety, comparators
Main presentation	Read discussant tone, subgroups, durability, AEs
1 week post-presentation	Confirm sell-side and flow follow-through
1 month post-event	Without licensing / partnering / follow-up papers, event premium compresses

10. Valuation — market-implied success probability

10.1 Clinical-bio rNPV basic form

rNPV =
 Σ [future cash flow × success probability / (1 + discount rate)^t]
 + upfront expectation
 + milestone expectation
 - future R&D
 - SG&A
 - dilution cost
 + net cash

10.2 Market-implied success probability

Implied SuccProb =
 (Current EV - net cash - legacy business value - other pipeline value)
 ÷ unrisked NPV of the asset

The reason this matters is simple. Biotech equity is not “high success probability” — it’s the gap between market-implied success probability and your internal estimate.

Example:

Current EV: ₩1,000bn
Net cash: ₩200bn
Legacy business: ₩100bn
Other pipeline: ₩100bn

Implied core-asset value
= ₩1,000bn - ₩200bn - ₩100bn - ₩100bn
= ₩600bn

Core-asset unrisked NPV: ₩2,000bn

Implied success probability
= ₩600bn / ₩2,000bn
= 30%

Cross-check: ₩2,000bn × 30% = ₩600bn. Rounded to ₩100bn.

If internal estimate is 45%, undervalued. 15%, overvalued. That gap is the alpha source.

11. Research methodology — primary-source priority

Priority	Source	Key fields
1	DART	Cash, CB/BW, top shareholder, licensing contracts, material disclosures
1	ClinicalTrials.gov / CRIS / MFDS	Phase, enrollment status, endpoints, primary completion date
1	Official conference abstract	Patient count, endpoints, safety, presentation format
1	Patent database	Composition / use patents, platform scope
1	KRX	Short-sale, securities-lending, investor-segment flow, turnover
2	Papers / guidelines	Competitor benchmarks, indication-specific endpoints
2	Sell-side reports	Consensus and market narrative
3	News / IR / community	Sentiment / overheating

ClinicalTrials.gov primary-completion-date = date of final data collection for primary outcome (last participant examined / intervened). In practice, registry primary-completion-date drift matters more than company-stated “expected readout dates”.

12. Name priority

Priority	Name	Classification	Core reasoning	Core risk
1	D&D Pharmatech	Event-driven watchlist	DD01 EASL 48-week biopsy data	Sharp drop if fibrosis weak
2	LegoChem Bio	Conditional watchlist	ADC platform, ASCO + partner optionality	Pre-priced expectations, toxicity / competition
3	Alteogen	Core watchlist	SC-conversion royalty platform	Real-world conversion / valuation
4	Voronoi	Wait	VRN11 CNS data	Patient count / follow-up limits
5	Samsung Biologics	Wait / quality on weakness	1Q26 print + CDMO utilization	Valuation / labor / quality risk
6	GI Innovation	Speculative watchlist	ASCO Rapid Oral Abstract	Phase 1 limits
7	Lunit	Watchlist	AI-biomarker ASCO validation	Lag vs. NCE licensing revenue
8	Yuhan / Hanmi / Olix	Read-through watchlist	MASH / obesity theme	No direct data or delay

13. Invalidation conditions

When each thesis breaks, the signal is specific.

Thesis	Invalidation
ADC / oncology BD	ASCO data shows no differentiation vs. competitors, toxicity events
MASH	Insufficient fibrosis improvement or MASH resolution
SC-conversion platform	Weak real-world conversion, unclear royalty economics
CDMO	Utilization decline, new-order slowdown, quality / delivery issues
Biosimilars	Regulatory deregulation outweighed by price-competition intensification
FDA real-time clinical	Pilot scope narrow, no Korean-company application
Undervaluation logic	Market-implied probability rises above internal estimate

14. Bottom line

Korean biotech right now is not a “pick good names” market — it’s a “pick names whose good data the market has under-priced” market. ASCO and EASL are powerful catalysts, but buying on abstract acceptance alone is low-grade event trading.

D&D Pharmatech is the cleanest binary; LegoChem Bio is the textbook BD-optionality name; Alteogen is the highest-quality royalty platform. Conversely, story-only names in obesity / ADC / cell-gene therapy without actual data are the explicit avoid list.

The single discipline that matters in this sector: don’t believe the technology; believe the data and the cash runway. Late-May congresses are the first verification gate; the June ADA is the follow-on. The licensing / partnering / follow-up papers in the month after the events set the final price.

FAQ

Q: Why is D&D Pharmatech #1? A: At EASL Congress 2026 (May 27-30), DD01 Phase 2 48-week data will be presented as a Late-Breaking Abstract. The MASH endpoint that matters most — biopsy-confirmed liver-fibrosis improvement — is disclosed. Good data triggers re-rating against global MASH comparables; weak data triggers a sharp drop. The cleanest binary structure of the cohort.

Q: Why isn’t ASCO abstract acceptance enough to buy? A: Acceptance is not a guarantee of data quality. What actually matters: ORR, PFS, OS, DoR, Grade 3/4 AEs, discontinuation, dose-response. Buying purely on acceptance leads to sell-the-news when post-release data turns out average.

Q: How is Alteogen different from clinical biotech? A: Alteogen’s value is not in one drug’s clinical success — it’s in capturing as royalty the economic value of administration convenience and clinic-throughput improvements when IV formulations convert to SC. As real-world prescription-conversion data accumulates, the valuation can re-rate from “single-event bio” to “royalty DCF.” Binary-event risk is structurally lower.

Q: Why isn’t Samsung Biologics #1? A: 1Q26 print is strong (revenue ₩1,257.1bn, OP ₩580.8bn). But unlike event biotech, short-term conference catalysts are limited. Valuation, plus labor / quality risk, has to be priced. CDMO is a “on weakness” candidate, not a chase.

Q: Is FDA deregulation an immediate tailwind? A: Long-dated option, limited short-term effect. PK-trial cost cuts (up to 50%, ~$20M) and the real-time clinical-trials initiative are sector-positive but Korean small-to-mid-cap biotech is unlikely to be an early beneficiary. Names with US clinical infrastructure benefit first.

Q: How do you calculate market-implied success probability? A: (Current EV − net cash − legacy business − other pipeline) ÷ core-asset unrisked NPV. If that ratio is below your internal estimate, undervalued. The Section 10 worked example shows EV ₩1tn + core-asset NPV ₩2tn → implied 30%.

Q: Which sources to read first? A: DART (disclosures), ClinicalTrials.gov (phase, endpoints, completion dates), official conference abstracts (patient count, safety, format), patent databases, KRX (short / lending / segment flow). Sell-side reports for consensus; news / IR for sentiment temperature. Registry primary-completion-date drift is a more reliable signal than company-stated “expected readout” timing.

This article is for research and informational purposes only and does not constitute investment advice. Conference dates and abstract-release timing follow ASCO / EASL / EHA / ASGCT / ADA official sources. FDA biosimilar draft guidance and real-time clinical-trials initiative reference FDA press materials (March / April 2026). Samsung Biologics 1Q26 figures are from official disclosure. D&D Pharmatech DD01 / Voronoi VRN11 / GI Innovation GI-101A / Lunit SCOPE references are from each company’s official releases and conference-acceptance announcements. The market-implied-probability example uses a generic framework; actual name-level values require live price, net cash, and pipeline-specific assumptions. Event-impact scores (3/5, 5/5) are analytical estimates and can diverge from actual outcomes. Analysis can be wrong. Data cut: May 12, 2026 KST.

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

KOSDAQ Complete Guide for Foreign Investors — 1,820 Listed Companies, About to Be Sliced Into a 3-Tier League. October 2026 Promotion / Relegation Reform Could Finally Open the Pension-Capital Tap

Sun, 10 May 2026 11:00:00 +0900

📚 KOSDAQ Series — Part 1. Continue with: Part 2 — Screening for Quality with ROE: 1,820 → 105 → 35 → 6

While KOSPI breached 7,500 and printed an all-time market-cap high, KOSDAQ has been oscillating around the 1,200 line. YTD 2026 the small-cap board is +30% — not bad in absolute terms, ahead of Turkey, Japan, and Brazil — but less than half of KOSPI’s +75%. The retail-investor complaint is by now familiar: “KOSDAQ doesn’t go up when KOSPI goes up, and goes down when KOSPI goes down.” Underneath the relative-performance frustration, however, the structural change worth tracking has finally surfaced: a promotion-relegation system that splits all ~1,820 KOSDAQ-listed companies into Premium (Tier 1, ≤100 names), Standard (Tier 2), and Watch (Tier 3) segments, with movement between tiers based on earnings and governance. The reform launches as early as October 2026. The point is not to publish another curated list — the 2022 KOSDAQ Global Index already proved the curation worked but the money didn’t follow. This time the design must build the buy-side plumbing too.

TL;DR

What KOSDAQ is. Korea’s growth-equity board, launched in 1996 as a NASDAQ analog. ~1,820 listed companies. Dominated by biotech, semiconductor equipment, gaming, beauty, robotics, battery-materials. The “next-generation Samsung Electronics” tends to start its public-market life here.
Up +30% YTD but overshadowed. That print beats Turkey (+29%), Japan (+18%), Brazil (+16%). But against KOSPI +75%, it reads as relative underperformance — KOSPI’s rally was that large, not because KOSDAQ collapsed.
A 25-year breakout. April 24, 2026 closed at 1,203.84 — the first close above 1,200 since the dot-com peak in March 2000. Driven by breadth (semiconductor-equipment, biotech, robotics, batteries) rather than a single-theme rip.
The reform that matters: October 2026 promotion-relegation. All ~1,820 listed names get split into Premium (≤100), Standard, and Watch. Earnings-based promotion and relegation. The intent: build the institutional plumbing (premium-segment ETFs, NPS benchmark inclusion, ₩6tn People’s Growth Fund) so passive and pension capital have forced exposure to the curated top tier rather than optional.
The legacy problem the reform is trying to fix. KOSDAQ’s index-level top names skew toward names with elevated multiples and unproven earnings — Ecopro BM at PER ~596×, LegoChem Bio at ~286×, Robotis at ~390×, ABL Bio loss-making but at #9 by market cap. A KOSDAQ150 mechanically tilted toward unprofitable names is exactly the kind of benchmark institutions cannot underwrite.
Premium-segment success requires actual buy demand, not just the list. The 2022 KOSDAQ Global Index returned +160% vs. KOSDAQ broad +65% — proving curation works. But it never became a pension benchmark or an ETF magnet. The October reform must avoid that trap.
Why this matters at the name level. Stocks already covered in our prior posts that sit on KOSDAQ — ISU Petasys (substrate stack), OE Solutions (CPO), APR (beauty), Easy Bio (feed-additive platform) — see different forward valuations depending on Premium-tier inclusion. Inclusion = passive flow + NPS attention + liquidity uplift. Exclusion = retail-flow status quo.

1. What KOSDAQ Is — for foreign investors arriving fresh

1.1 Korea’s “second exchange”

Item	KOSPI	KOSDAQ
Character	Large-cap, blue-chip	Growth, innovation
Launched	1956	1996
Listed companies	~950	~1,820
Market cap	~₩6,000tn (8th globally)	~₩673tn
Sector tilt	Semis, autos, financials, energy, shipbuilding	Biotech, semi-equipment, gaming, beauty, robotics
Investor base	Foreign / institutional dominant	Retail dominant (64% of trading volume)
Volatility	Lower	Higher
Index base	1980-01-04 = 100	1996-07-01 = 1,000
Flagship index	KOSPI 200	KOSDAQ 150

KOSPI is the home of Samsung Electronics, SK hynix, Hyundai Motor. KOSDAQ is where the next generation lives. Mapped to the U.S., KOSPI ≈ NYSE and KOSDAQ ≈ NASDAQ.

1.2 The name and the original mission

KOSDAQ stands for Korea Securities Dealers Automated Quotation — a deliberate echo of NASDAQ. The launch mandate was to give SMEs, ventures, and tech companies an equity-funding path that KOSPI’s stricter listing thresholds wouldn’t allow. The Financial Services Commission still describes KOSDAQ as “the core infrastructure of Korea’s innovation and venture ecosystem.”

1.3 KOSDAQ vs. NASDAQ — where they diverge

Item	U.S. NASDAQ	Korea KOSDAQ
Market cap	~$29tn (#1 globally)	~₩673tn (~$500bn)
Flagship names	Apple, Nvidia, Microsoft	Alteogen, Ecopro BM, HLB, Leeno Industrial
Institutional weight	High	Low (retail = 64% volume)
Hosts mega-caps?	Yes (Apple ~$4tn cap)	No (large-caps migrate to KOSPI)
Market perception	“World’s leading tech-stock board”	“Volatile, sometimes speculative”

The single most important divergence: NASDAQ keeps Apple and Nvidia. KOSDAQ loses its winners to KOSPI. 54 companies have transferred from KOSDAQ to KOSPI since launch; the 48 still listed today have a combined market cap of ~₩218tn — more than 30% of KOSDAQ’s entire market cap. The structural weakness is built in: the best-performing companies leave the board. Closing this leak is one of the explicit goals of the October promotion-relegation reform.

2. KOSDAQ’s 30 years — boom, collapse, and a 25-year recovery

2.1 Compressed history

1996.07: Launched at 1,000
1997-1998: Asian financial crisis collapse
2000.03: 2,834 ← all-time high (dot-com peak; not yet broken)
2000.12: 525 ← bubble burst, -80%
2001-2019: Range-bound 400-900 — the "lost two decades"
2020: COVID-low rebound, retail-investor onboarding wave
2022-2024: Rate hikes, capital-gains-tax debate, drift back to 600-800
2025 H2: Government KOSDAQ-revitalization program
2026.01.26: Reclaims 1,000
2026.04.24: Closes at 1,203.84 → first 1,200+ close in 25 years
2026.05: Oscillating around 1,200

2.2 Why the 25-year breakout matters

KOSDAQ has approached 1,200 multiple times and failed each time. The April 2026 break is different because the move was driven by breadth — semiconductor materials/equipment, biotech, robotics, and batteries simultaneously — rather than a single thematic rip.

The relative gap to KOSPI is real and hurts perception. On May 6, KOSPI surged +447 points (+6.5%) and broke 7,000 — KOSDAQ closed -0.3% the same session. “Doesn’t rally with KOSPI, sells off with KOSPI” is the retail complaint that crystallized.

But KOSDAQ +30% YTD is genuinely not bad in absolute terms — it’s ahead of Turkey (+29%), Japan (+18%), Brazil (+16%). The relative softness is a function of KOSPI’s outsized rally, not KOSDAQ deterioration. Why Korea Part 4 covers the $6.7bn foreign ETF inflow that overwhelmingly went to Samsung Electronics and SK hynix — i.e., to KOSPI, not to KOSDAQ. The October reform is one of the explicit channels for redirecting that capital.

3. What’s actually inside KOSDAQ — by sector

3.1 Biotech / pharma — the biggest segment

Most of KOSDAQ’s index-cap top sits in biotech. Korea has begun building real strength in biosimilars, antibody-drug conjugates (ADCs), and cell-and-gene therapy.

Alteogen — subcutaneous-injection drug-delivery platform, licensed to global pharma. Among the largest names in KOSDAQ by market cap.
LegoChem Biosciences — ADC platform with multiple large licensing deals.
ABL Bio — bispecific antibodies. ~#9 by market cap despite a projected ₩48.6bn loss this year.
Kolon TissueGene — gene therapy for osteoarthritis.

The sector is KOSDAQ’s biggest strength and its biggest volatility source. Names move +100% on trial reads and -50% on accounting issues. SamCheonDang Pharmaceutical hit #1 in KOSDAQ market cap at a ₩1.23m share price in March 2026, then collapsed below ₩400k after disclosure-failure designations — a textbook KOSDAQ episode.

3.2 Semiconductor equipment / materials — the AI second derivative

If KOSPI hosts Samsung Electronics and SK hynix, KOSDAQ hosts most of their suppliers.

Jusung Engineering — semiconductor and display deposition equipment.
Wonik IPS — wafer-process equipment.
Leeno Industrial — test sockets and probe pins, leading global market share.
Hanmi Semiconductor — back-end equipment with HBM exposure (a key 2025-2026 AI beneficiary).
ISU Petasys — high-layer-count PCBs for AI servers and switches. Covered in Korea AI PCB Ecosystem: 10 Companies.
OE Solutions — optical transceivers and laser chips, with CPO-related external-light-source products. Covered in Korea Optical / CPO Value Chain — 7 Companies.

This is the segment doing most of the heavy lifting in 2026’s KOSDAQ rally.

3.3 Gaming, beauty, robotics, batteries — the cluster names

Gaming: Pearl Abyss (Black Desert / Crimson Desert global MMORPGs), Wemade, Com2uS, Kakao Games.
Beauty: Classys (medical aesthetics devices, HIFU), PharmaResearch (Rejuran PN skin booster, polynucleotide platform), Silicon2 (global K-beauty distribution platform), Englewood Lab (US-market beauty ODM). See Why Korea Part 2 — Korean Cosmetics for the ecosystem context. Note: APR (KOSPI 278470) and Cosmax (KOSPI 192820) — both well-known Korean beauty names — are KOSPI-listed and outside the scope of this KOSDAQ guide.
Robotics: Rainbow Robotics (bipedal humanoid with Samsung Electronics as strategic investor).
Battery materials: Ecopro BM (cathodes, near top of KOSDAQ market cap, projected PER ~596×).

4. Why KOSDAQ has carried a “casino-board” reputation

4.1 Top-of-cap names with unverified earnings

The Maeil Business Newspaper framing is sharp: KOSDAQ’s highest-market-cap tier is dominated by names with elevated multiples and unproven earnings.

Name	Market cap	2026E net income	Implied PER
Ecopro BM	₩23tn+	Tens of ₩bn	~596×
LegoChem Bio	₩7tn+	~₩40bn	~286×
Robotis	₩5tn	~₩10bn	~390×
ABL Bio	#9 by market cap	-₩48.6bn (loss)	n/m

High multiples on growth names are not, in themselves, a problem — NASDAQ also hosts loss-making names at the cap top. The actual issue is structural: when index methodology elevates unverified-earnings names into KOSDAQ 150, the benchmark itself becomes uninvestable for institutions whose mandates require profitability filters.

4.2 The KOSDAQ 150 design problem

KOSDAQ 150 selects on free-float market cap and trading volume. Under that filter, unprofitable thematic names (battery-materials, biotech, robotics) with inflated caps from expectation alone end up in the index ahead of profitable mid-caps with stable earnings. Pension funds running KOSDAQ 150 as a benchmark are then forced to underwrite that mix. They mostly choose not to.

4.3 The good companies leave for KOSPI

KOSDAQ’s most-successful graduates transfer up to KOSPI to access deeper institutional and foreign liquidity, plus larger passive pools. 54 companies have made that move; the 48 still listed today carry ~₩218tn of market cap — over 30% of KOSDAQ’s total. The board’s structural weakness is that its winners exit.

5. The October Reform — a 3-tier league with promotion and relegation

5.1 What changes

From October 2026 (or as soon as feasible), KOSDAQ’s ~1,820 listed companies get sorted into three tiers:

Premium (Tier 1):
- ≤100 companies
- Selection on financial soundness, growth, governance
- Designed as the destination for pension and passive flows
- New dedicated index + ETF products

Standard (Tier 2):
- Mid- and small-caps below the Premium threshold
- Separate index and ETF products under consideration
- Provides depth, mitigates Premium-only flow concentration

Watch (Tier 3):
- Distressed / problem names
- Accelerated delisting pathway

The promotion-relegation logic is direct: companies move between tiers based on earnings and governance metrics. Same idea as football-league relegation, applied to capital markets.

5.2 Why this matters — “a good list” ≠ “a list institutions must own”

A market-participant quote captures the design lesson:

“We made a list of good companies, but we never built a structure that forces investors to actually own them.”

That refers to the 2022 KOSDAQ Global Index: ~50 selected names, +160% return since launch (vs. KOSDAQ broad +65% same period). The curation worked. The flow didn’t. ETFs tracking the Global Index stayed small. NPS never adopted it as a core benchmark. The October reform’s design intent is to fix that — move beyond curation and build the institutional flow architecture into the system itself.

5.3 Specifically, what flow channels open

1. Premium-index passive flow. A dedicated Premium index becomes the underlying for new ETFs. Passive AUM mechanically buys the Premium 100 — separate from existing KOSDAQ 150 passive demand.

2. NPS benchmark inclusion. If the National Pension Service’s domestic-equity benchmark begins to assign weight to KOSDAQ (per reform discussions, ~5%), then funds and external managers ignoring KOSDAQ underperform their benchmark. “Not buying” becomes a relative-performance penalty rather than a neutral choice.

3. People’s Growth Fund. A ₩150tn (5-year) People’s Growth Fund is being aligned with KOSDAQ. Of the ₩30tn scheduled this year, ₩10tn flows into equity / indirect investment, including special-listing tech companies and pre-listing KOSDAQ pipeline. The ₩600bn People’s Participating subfund launching May 22 carries a minimum 10% (₩60bn) allocation requirement to KOSDAQ tech-special-listing names.

5.4 The “stop the leak to KOSPI” effect

If Premium-tier names can access pension money and passive flows while staying on KOSDAQ, the incentive to transfer up to KOSPI weakens. The structural leak that has cost KOSDAQ its winners for 25 years could finally be plugged.

5.5 Timeline

Now: Korea Capital Market Institute (KCMI) finalizing detail design
June: Market-participant briefings, public comment
July: KOSDAQ 30th-anniversary event — formal disclosure of the reform framework
October (target): Reform goes live

6. The ratio that matters — 50 well-chosen names vs. the broad index

6.1 What the KOSDAQ Global Index already proved

KOSDAQ Global Index (\~50 quality names):
2022.11.21 inception (1,000) → 2026.05.08 (2,602) → +160.2%

Same period:
KOSDAQ broad (\~1,800 names): +65%
KOSDAQ 150 (150 names): +93%
KOSDAQ Global (\~50 names): +160%

The selection-method matters more than KOSDAQ-the-asset-class. Choosing 50 well-screened names returned ~2.5× the broad index. “KOSDAQ doesn’t work” is the wrong framing. “Which KOSDAQ names you own” is the question.

6.2 Premium selection must be earnings-based, not just cap-based

The legacy KOSDAQ 150 was effectively cap-and-volume. That filter inevitably promoted unverified-earnings names — Ecopro BM at PER ~596×, ABL Bio loss-making, Robotis at PER ~390×. The Premium-tier brief explicitly cites financial soundness and growth as the selection criteria. If the implementation actually screens out cap-only names, the resulting benchmark is institutionally underwriteable in a way KOSDAQ 150 has never been.

7. Why this matters for the names we already cover

7.1 KOSDAQ-listed names from our prior posts

ISU Petasys — covered in Korea AI PCB Ecosystem: 10 Companies.
OE Solutions — covered in Korea Optical / CPO Value Chain — 7 Companies.
Easy Bio — covered in Part 1 and Part 2.
Silicon2 / Pamicell — covered in the ROE-25% screen.

For each of these, Premium-tier inclusion is a non-trivial valuation variable.

If included:

Mechanical passive-fund inflow via Premium-index ETFs
NPS-benchmark consideration
Liquidity-tier improvement
Multiple-rerating optionality on the back of cleaner buy-side access

If not included:

Retail-flow regime continues
Institutional access remains gated

7.2 The variables to track from October

The Premium 100 list itself — earnings-based or cap-based? The single most important reveal.
ETF launch pace and AUM — does Premium-index passive AUM reach a meaningful scale?
NPS benchmark adoption — does KOSDAQ actually enter the pension benchmark?
People’s Growth Fund deployment — does the ₩600bn participating subfund meaningfully invest in KOSDAQ tech names?
KOSPI transfer activity — do Premium-tier names stop migrating up to KOSPI?

8. Risks that could neutralize the reform

8.1 “List changes, money doesn’t”

The 2022 KOSDAQ Global Index outcome could repeat. Premium list curated, ETFs launched, but AUM stays small and NPS doesn’t adopt it as a benchmark. Without the institutional pull, capital-flow patterns don’t shift.

8.2 Thematic volatility persists

The reform doesn’t lower KOSDAQ volatility per se. Among the ~1,720 non-Premium names, retail-driven theme rallies and crashes will continue. The “KOSDAQ is risky” perception doesn’t dissolve overnight.

8.3 Diluted Premium criteria

If the Premium tier ends up including loss-making or unverified-earnings names — to satisfy lobbying or political optics — the credibility premise collapses. The criterion has to be earnings, not market cap. Anything else recreates the KOSDAQ 150 problem under a new name.

9. Bottom line

KOSDAQ is a 30-year-old market that still hasn’t recovered its 2,834 dot-com peak. Twenty-five years of “lost market” status. YTD 2026 is +30% with a 1,200 breakout — but KOSPI’s +75% has overshadowed the move and produced more retail frustration than appreciation.

The structural change worth tracking is the October promotion-relegation reform. Splitting ~1,820 listed names into Premium (≤100), Standard, and Watch, with movement based on earnings, is one piece. The piece that matters more is building the institutional plumbing — Premium-index ETFs, NPS-benchmark inclusion, People’s Growth Fund alignment — that forces real flow into the new top tier. If those three pieces work, KOSDAQ-quality names see liquidity and multiple uplift.

The KOSDAQ Global Index already proved the upper bound: 50 well-chosen names returned +160% while the broad index returned +65%. “KOSDAQ doesn’t work” was always the wrong framing. “Which 50 names” was the question. The October reform’s success or failure compresses to two design choices — does the Premium screen prioritize earnings over cap, and does the institutional plumbing actually pull flow.

FAQ

Q: How does KOSDAQ differ from KOSPI for foreign investors? A: KOSPI is large-cap blue-chip (Samsung Electronics, SK hynix, Hyundai Motor, ~950 names); KOSDAQ is growth (biotech, semi-equipment, gaming, robotics, ~1,820 names). U.S. analog: NYSE vs. NASDAQ. KOSDAQ is more volatile and far more retail-dominated.

Q: Who is the largest company on KOSDAQ? A: It rotates frequently. Recently Alteogen, Ecopro BM, HLB, and Leeno Industrial have traded near the top. Because KOSDAQ’s biggest winners migrate to KOSPI (54 names historically — APR and Cosmax are recent examples), KOSDAQ’s “leader” is structurally a newer cohort rather than a stable Apple-equivalent.

Q: Why has KOSDAQ underperformed KOSPI in 2026? A: The $6.7bn YTD foreign ETF flow concentrated in KOSPI mega-caps (Samsung Electronics, SK hynix). KOSDAQ is retail-dominated and pension/foreign access is structurally limited. The October promotion-relegation reform is the explicit attempt to redirect institutional flow into KOSDAQ Premium-tier names.

Q: What does the promotion-relegation system actually do? A: It splits ~1,820 KOSDAQ names into Premium (≤100), Standard, and Watch, with movement between tiers tied to earnings. Combined with new Premium-index ETFs, NPS-benchmark inclusion, and the People’s Growth Fund, the design forces pension and passive capital into the curated top tier. The intent is to break the 25-year leak of KOSDAQ winners to KOSPI.

Q: Which KOSDAQ stocks should I watch around the October reform? A: Focus on profitable mid-caps with sustainable margins — Leeno Industrial, Hanmi Semiconductor, Classys, PharmaResearch, Easy Bio, etc. — that could plausibly meet earnings-based Premium criteria. The list itself is finalized only after October; pre-positioning carries category risk.

Q: What’s the biggest risk that the reform fails? A: The 2022 KOSDAQ Global Index outcome repeating — the Premium list gets curated, ETFs launch but stay small, NPS doesn’t adopt it as a benchmark. Without the buy-side plumbing actually engaging, the new list won’t change flow patterns.

Q: Which KOSDAQ stocks see the largest foreign-investor presence today? A: Names with high foreign-ownership ratios include Alteogen, Leeno Industrial, and HLB. Mostly companies with high overseas-revenue mix, or biotech names with advanced clinical pipelines.

This article is for research and informational purposes only and does not constitute investment advice. Reform-related details rely on Maeil Business Newspaper (2026-05-10, Kim Jung-suk) reporting. KOSDAQ index, market cap, listed-company count, and KOSPI-transfer history sourced from KRX. KOSDAQ Global Index returns from KRX disclosures. KOSDAQ-revitalization policy from FSC (2025-12-19) announcements. KOSDAQ 150 valuation data via FnGuide consensus. Relative-performance and foreign-flow context drawn from Seoul Economic Daily, NewDaily, EBN, and eToday reporting. KB Asset Management’s KOSDAQ Leader fund context from Seoul Economic Daily (2026-05-08). The promotion-relegation reform is not yet finalized — selection criteria, the Premium 100 list, and the launch date may change. Analysis can be wrong. Data cut: May 10, 2026 KST.